<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Modeling COVID-19 disease processes by remote elicitation of causal Bayesian networks from medical experts</title>
				<funder>
					<orgName type="full">Australian Commonwealth Government&apos;s Cooperative Research Centres Programme</orgName>
				</funder>
				<funder>
					<orgName type="full">Digital Health CRC</orgName>
				</funder>
				<funder>
					<orgName type="full">Snow Medical Research Foundation</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Steven</forename><surname>Mascaro</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">Bayesian Intelligence Pty Ltd</orgName>
								<address>
									<postCode>3158</postCode>
									<settlement>Upwey</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yue</forename><surname>Wu</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">School of Public Health</orgName>
								<orgName type="institution">University of Sydney</orgName>
								<address>
									<postCode>2006</postCode>
									<settlement>Camperdown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Owen</forename><surname>Woodberry</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">Bayesian Intelligence Pty Ltd</orgName>
								<address>
									<postCode>3158</postCode>
									<settlement>Upwey</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Erik</forename><forename type="middle">P</forename><surname>Nyberg</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ross</forename><surname>Pearson</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jessica</forename><forename type="middle">A</forename><surname>Ramsay</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Wesfarmers Centre of Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Insti- tute</orgName>
								<orgName type="institution" key="instit2">University of Western Australia</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ariel</forename><forename type="middle">O</forename><surname>Mace</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Wesfarmers Centre of Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Insti- tute</orgName>
								<orgName type="institution" key="instit2">University of Western Australia</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Depart- ment of General Paediatrics</orgName>
								<orgName type="institution">Perth Children&apos;s Hospital</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Paediatrics</orgName>
								<orgName type="institution">Fiona Stanley Hospital</orgName>
								<address>
									<postCode>6150</postCode>
									<settlement>Murdoch</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">A</forename><surname>Foley</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Wesfarmers Centre of Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Insti- tute</orgName>
								<orgName type="institution" key="instit2">University of Western Australia</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="laboratory">PathWest Laboratory Medicine</orgName>
								<address>
									<postCode>6909</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><forename type="middle">L</forename><surname>Snelling</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">School of Public Health</orgName>
								<orgName type="institution">University of Sydney</orgName>
								<address>
									<postCode>2006</postCode>
									<settlement>Camperdown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">Wesfarmers Centre of Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Insti- tute</orgName>
								<orgName type="institution" key="instit2">University of Western Australia</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">School of Public Health</orgName>
								<orgName type="institution">Curtin University</orgName>
								<address>
									<postCode>6102</postCode>
									<settlement>Bentley</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">Menzies School of Health Research</orgName>
								<orgName type="institution" key="instit2">Charles Darwin University</orgName>
								<address>
									<postCode>0815</postCode>
									<settlement>Darwin</settlement>
									<region>NT</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Ann</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
							<email>ann.nicholson@monash.edu</email>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Covid</forename><surname>Bn</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Advisory</forename><surname>Group</surname></persName>
						</author>
						<title level="a" type="main">Modeling COVID-19 disease processes by remote elicitation of causal Bayesian networks from medical experts</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1186/s12874-023-01856-1</idno>
					<note type="submission">Received: 1 May 2022 Accepted: 30 January 2023</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.1" ident="GROBID" when="2025-10-28T22:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>COVID-19</term>
					<term>Pathophysiology</term>
					<term>Bayesian network</term>
					<term>DAG</term>
					<term>DBN</term>
					<term>Causal model</term>
					<term>Expert elicitation</term>
					<term>Decision support</term>
					<term>Experimental design</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Background COVID-19 is a new multi-organ disease causing considerable worldwide morbidity and mortality. While many recognized pathophysiological mechanisms are involved, their exact causal relationships remain opaque. Better understanding is needed for predicting their progression, targeting therapeutic approaches, and improving patient outcomes. While many mathematical causal models describe COVID-19 epidemiology, none have described its pathophysiology.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>In early 2020, we began developing such causal models. The SARS-CoV-2 virus's rapid and extensive spread made this particularly difficult: no large patient datasets were publicly available; the medical literature was flooded with sometimes conflicting pre-review reports; and clinicians in many countries had little time for academic consultations. We used Bayesian network (BN) models, which provide powerful calculation tools and directed acyclic graphs (DAGs) as comprehensible causal maps. Hence, they can incorporate both expert opinion and numerical data, and produce explainable, updatable results. To obtain the DAGs, we used extensive expert elicitation (exploiting Australia's exceptionally low COVID-19 burden) in structured online sessions. Groups of clinical and other specialists were enlisted to filter, interpret and discuss the literature and develop a current consensus. We encouraged inclusion of theoretically salient latent (unobservable) variables, likely mechanisms by extrapolation from other diseases, and documented supporting literature while noting controversies. Our method was iterative and incremental: systematically refining and validating the group output using one-on-one follow-up meetings with original and new experts. 35 experts contributed 126 hours face-to-face, and could review our products.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>We present two key models, for the initial infection of the respiratory tract and the possible progression to complications, as causal DAGs and BNs with corresponding verbal descriptions, dictionaries and sources. These are the first published causal models of COVID-19 pathophysiology.</p><p>Conclusions Our method demonstrates an improved procedure for developing BNs via expert elicitation, which other teams can implement to model emergent complex phenomena. Our results have three anticipated applications: (i) freely disseminating updatable expert knowledge; (ii) guiding design and analysis of observational and clinical studies; (iii) developing and validating automated tools for causal reasoning and decision support. We are</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>COVID-19 is a new multi-organ disease, caused by the highly infectious SARS-CoV-2 virus, resulting in considerable worldwide morbidity and mortality. While many recognized pathophysiological mechanisms are involved-coagulation and inflammatory cascades, pulmonary exudation and respiratory compensation, endovascular and renal injury-the exact causal relationships between them remain opaque. A better understanding of these causal processes is urgent and important for predicting their progression, targeting therapeutic approaches and improving patient outcomes. To this end, the worldwide pandemic generated a flood of research, but much of the early output was unfiltered, sometimes conflicting, and of reduced reliability <ref type="bibr" target="#b0">[1]</ref>. In contrast, no large patient datasets were publicly available, and even now, their data remains limited.</p><p>In this project, we used online tools to enlist independent medical experts to interpret and iteratively discuss the evolving literature, providing us with consensus views. This process resulted in the elicitation of several detailed graphical causal models of the pathophysiology underlying the clinical manifestations of COVID-19 disease, using the kind of iterative, incremental method widely recommended for model building <ref type="bibr" target="#b1">[2]</ref>, but rarely realized in expert knowledge elicitation. From these theoretical products, simplified models can be constructed for practical application that are parameterized using available data, e.g., for predicting the probability of a patient's future need for intensive care given their current signs, symptoms and laboratory results.</p><p>In this paper, we make freely available our expert-elicited models. While there has been considerable prior work developing causal models of the transmission of SARS-CoV-2 within populations <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>, ours are the first causal models of the COVID-19 disease process within individuals. We anticipate that these models will serve three purposes for our team and other researchers. First, they will aid communication and theoretical understanding, providing a common causal knowledge base which can be readily updated to incorporate new knowledge and hypotheses. Second, they will guide the design and analysis of both observational and clinical studies into COVID-19, by identifying potential mediators, confounders and potential sources of biases and errors. Importantly, this includes informing the design of data collection studies and standards, supporting their ability to produce data that is suitable for statistical and, particularly, causal analysis. Third, they are provided to all in the hope that they be used to derive, develop and validate bespoke parameterized models and practical tools for causal reasoning and decision support, both in clinical and policy settings.</p><p>It is critical to understand how the causal models described here can achieve these three purposes. We expect the manner in which they provide a common causal knowledge base should be readily apparent from the description of the models in Results. The ways in which they support empirical studies and also the development of practical parameterized models require their own discussion, and are described in Discussion and conclusion. While the full development of any particular parameterized model is beyond the scope of this paper (involving many additional techniques around development, analysis and validation), we do outline how such models can be (and have been) derived from the causal models towards the end of this paper, using examples from our own subsequent work <ref type="foot" target="#foot_0">1</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Causal Bayesian networks</head><p>Bayesian networks (BNs) were designed to model probabilistic causal systems. Formally, a BN <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13]</ref> includes a directed, acyclic graph (DAG), (e.g., Fig. <ref type="figure">1</ref>), which consists of nodes connected by arcs (pointing from 'parent' to 'child') that never point in a continuous sequence from a node back to itself <ref type="foot" target="#foot_1">2</ref> . In addition, in a BN each node represents a random variable with multiple possible states, and each arc represents a direct probabilistic dependency, quantified by a conditional probability table <ref type="bibr">(CPT)</ref> or equation specifying the probability distribution of the child given the states of all its parents. In causal DAGs and BNs, these arcs also represent direct causal influences-hence they can also predict the effects of decisions regarding interventions.</p><p>Readily available software 3 allows users to enter exact or uncertain evidence about any variables, which is then efficiently propagated to update the probability distributions for all variables. Thus, causal BNs can support and perform prognostic (predictive), diagnostic (retrodictive), explanatory and decision-oriented probabilistic reasoning.</p><p>In a BN, all arcs and nodes-even 'latent' ones, i.e., not directly observable-may be defined in a semantically meaningful way (as in Figs. <ref type="figure">1</ref> and<ref type="figure" target="#fig_0">2</ref>), and this will always be so when the BNs represent knowledge elicited from humans. This transparency is in stark contrast to the opaque "black boxes" of neural networks, where latent nodes are usually connected and parameterized based on a large dataset and do not have any readily discernible semantic or causal interpretation.</p><p>One important consequence is that an elicited BN can be readily updated to reflect new human knowledge, which is often derived from more than just a new dataset. Since it is clear which nodes the new knowledge relates to, we can usually identify a few locations where changes are needed while leaving the remainder of the network untouched. This can be extremely useful for complex emergent phenomena, where understanding is advancing rapidly while datasets remain small.</p><p>Another important consequence is that the BN structure and its inferences are potentially explainable, provided that the important aspects of a complicated BN or inference can be identified and clearly articulated. In medicine, for example, for ethical and practical reasons it is better if the recommendations of an AI tool are explainable and justifiable <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>. Algorithms for automatically generating such explanations, which supplement basic BN software by distilling complex inferences into a concentrated essence more palatable for human consumption, are a continuing focus of research, e.g., <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref>. These explanations are often better expressed in causal terms <ref type="bibr" target="#b20">[21]</ref>, including those supporting medical diagnoses <ref type="bibr" target="#b21">[22]</ref>.</p><p>Any causal BN entails a partial time order for its variables: parents precede their children. But a BN's capacity to represent time is limited, since cycles are prohibited and each variable usually appears only once, thus making Fig. <ref type="figure">1</ref> Causal DAG excerpt. These are the initial nodes of the Respiratory causal DAG provided in Additional file 1. The node 'Pulmonary capillary leakage', for example, has three 'parents' that jointly influence it, and two 'children' it influences. In the BN, provided in <ref type="bibr" target="#b13">[14]</ref>, the variable it represents has states and a CPT that are not shown in the DAG. All the nodes are named, numbered, and color coded for ease of reference, and corresponding definitions for variables and arcs are given in the associated Dictionary, Additional file 3, an excerpt from which is provided in Fig. <ref type="figure" target="#fig_0">2</ref> 3 We used the GeNIe BN software tool <ref type="bibr" target="#b56">[58]</ref> to elicit the BNs presented here, and Netica <ref type="bibr" target="#b57">[59]</ref> to develop and parameterize subsequent models from datasets. Other widely-used commercial BN software tools include Hugin <ref type="bibr" target="#b58">[60]</ref>, AgenaRisk <ref type="bibr" target="#b59">[61]</ref>, and BayesiaLab <ref type="bibr" target="#b60">[62]</ref>. In addition, research software and tools include Elvira <ref type="bibr" target="#b61">[63]</ref>, R BN libraries <ref type="bibr">[24]</ref>, BNT <ref type="bibr" target="#b62">[64]</ref>, SamIam <ref type="bibr" target="#b63">[65]</ref>, and BayesPy <ref type="bibr" target="#b64">[66]</ref>.</p><p>it difficult to represent both feedback loops and time series. A dynamic Bayesian network (DBN) <ref type="bibr" target="#b1">[2]</ref> is a BN in which a variable can be represented multiple times at different discrete time steps, and at any step T it may have parents at T, T -1 , T -2 , T -3, ... Hence, DBNs can model any complex multivariate time series, including feedback loops. If the structure of the network remains constant over time, the DBN can be compactly and cleanly represented as a network "snapshot" at a time step showing each variable's connections to all its parents.</p><p>We present our models as non-dynamic causal DAGs by focusing on the first instance at which each variable becomes involved, but have noted some feedback loops to facilitate their possible conversion to DBNs for modeling disease progression over longer time scales.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Building BNs by eliciting expert opinions</head><p>Given a large and representative numerical dataset, preferably supplemented by expert guidance on some causal directions, machine learning algorithms have been developed to find the sparsest causal BNs that could produce the observed dependencies, e.g., PC <ref type="bibr" target="#b12">[13]</ref>, CaMML <ref type="bibr" target="#b22">[23]</ref>, and R libraries such as bnlearn <ref type="bibr">[24]</ref>. In the absence of such a dataset, BN structure and/ or parameters-unlike those of opaque models-can be obtained entirely through knowledge elicitation from domain experts. This may be more time consuming, but has the essential advantage that expert knowledge usually represents a synthesis of multiple sources that can supplement and help interpret limited local data. Since domain experts usually have no prior exposure to BNs or training in causal inference, they need to be assisted by an expert BN modeler, who helps to express the knowledge in appropriate terms and highlight any important or missing pieces.</p><p>It is common to use multiple opinions rather than relying on only one source, with the hope of obtaining a larger pool of information and greater reliability from aggregated opinions, and perhaps benefiting from mutual feedback via discussion. Group elicitation of BNs has been particularly popular in some domains, such as reliability assessment <ref type="bibr" target="#b23">[25,</ref><ref type="bibr" target="#b24">26]</ref> and environmental research <ref type="bibr" target="#b25">[27]</ref>.</p><p>When group knowledge is pooled effectively, whether by collation, consensus, averaging, or another form of amalgamation, then it tends to outperform individual knowledge <ref type="bibr" target="#b26">[28]</ref><ref type="bibr" target="#b27">[29]</ref><ref type="bibr" target="#b28">[30]</ref><ref type="bibr" target="#b29">[31]</ref><ref type="bibr" target="#b30">[32]</ref><ref type="bibr" target="#b31">[33]</ref>. However, unstructured group interactions also bring well-documented problems, e.g., diffusion of responsibility, anchoring, "groupthink", deference to social status, and unproductive disputes <ref type="bibr" target="#b32">[34]</ref><ref type="bibr" target="#b33">[35]</ref><ref type="bibr" target="#b34">[36]</ref><ref type="bibr" target="#b35">[37]</ref><ref type="bibr" target="#b36">[38]</ref>. Such problems can be reduced by using structured protocols, e.g., collecting independent opinions from all participants prior to discussion, and also by using a moderator, e.g., to focus discussion on the most pressing issues, encourage only constructive contributions, and help establish a consensus where possible. A BN modeler with appropriate skills may also take the role of the moderator who leads discussion, which is the approach we used.</p><p>Software tools have recently been developed to support group elicitation of BNs, and the BARD tool <ref type="bibr" target="#b19">[20]</ref> includes multiple options to support highly structured protocols, including a strict version of the widely used Delphi technique <ref type="bibr" target="#b37">[39,</ref><ref type="bibr" target="#b38">40]</ref>. However, we needed to make the elicitation interactions as easy and quick as possible for our experts, so using only a videoconferencing tool (Zoom) with a modeler/facilitator who followed structured but flexible protocols was the most appropriate choice.</p><p>The way BNs are defined in Causal Bayesian networks might suggest that we build them in the same logical stages, like a waterfall: (i) define all the variables, so that we can (ii) specify all the arcs between them, and then (iii) estimate all the parameters this structure requires. However, for complex BNs this would require uncanny foresight. In contrast, as noted in <ref type="bibr" target="#b19">[20]</ref>, proposed methodologies for BN elicitation recommend proceeding iteratively and incrementally <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b39">[41]</ref><ref type="bibr" target="#b40">[42]</ref><ref type="bibr" target="#b41">[43]</ref>. More specifically, ( <ref type="bibr" target="#b1">[2]</ref>, Part III) suggests beginning with a small local structure around a target variable of interest, rather than attempting to exhaustively consider every possible factor relevant to the target. Subsequent iterations can pick up a few additional factors at a time, preferably with some form of validation in each iteration (e.g., feedback from an independent expert).</p><p>Another recommended strategy is to break down complex models into sub-models, and reuse common structures or elements when appropriate, dubbed "idioms" <ref type="bibr" target="#b42">[44]</ref>, "templates" <ref type="bibr" target="#b40">[42]</ref> and "network fragments" <ref type="bibr" target="#b39">[41]</ref>. These incremental approaches adapt similar ideas long used in software engineering, such as "spiral prototyping" or "agile model building" <ref type="bibr" target="#b43">[45]</ref>, and reusing common local structures is fundamental to "object-oriented" programming <ref type="bibr" target="#b44">[46]</ref>. An expert modeler/moderator can manage this workflow flexibly and efficiently as issues emerge.</p><p>If probabilities are elicited, then there is usually some degree of uncertainty and disagreement about them. Instead of a single point estimate for each probability, more thorough protocols have been designed to elicit several points (e.g., maximum, minimum, and best estimates) from each of multiple experts and combine this information <ref type="bibr" target="#b45">[47]</ref><ref type="bibr" target="#b46">[48]</ref><ref type="bibr" target="#b47">[49]</ref><ref type="bibr" target="#b48">[50]</ref>. Here, we are concerned principally with causal structure, with probabilities to be determined later from numerical datasets-although frequently experts provide rough indications of influence along with the variables and causal arcs, which can be captured by 'indicative' BN parameters and used for structure validation (see Elicitation sequences).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Our contributions</head><p>This paper makes two kinds of novel contributions to prior literature: in method and in results. In Methods, we demonstrate a structured approach that is only feasible using online tools, which manages to combine largescale group expert elicitation with BN building that is iterative, incremental, and includes validation. In Results, we present detailed causal DAGs and BNs (with indicative parameters), together with comprehensive associated documentation, that capture our experts' theoretical understanding of the corresponding COVID-19 pathophysiological processes. In Discussion and conclusion, we explain how researchers can use both our methods and results, and how we are currently doing so.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Our elicitation process was organized very quickly, relative to its scale and to similar projects with which any of the present authors have been involved. Organization included our initial planning for which models we wanted to develop, and hence what information we needed to elicit.</p><p>The process was exceptionally intensive, with many experts involved, a high degree of interest, and more detail captured in the expert models than usual. Centered in Australia, with its exceptionally low COVID-19 burden, we managed to obtain a very large number of consultation hours-mostly from experts around Australia, but supplemented by experts overseas. Many of these clinical experts therefore had little direct experience in treating COVID-19, with the exception of some overseas recruits with firsthand experience. Nevertheless, since their role was to interpret the available literature in the context of their existing domain knowledge rather than contribute original material, their expertise was adequate for our purposes. Furthermore, in high incidence settings, few experts would have had the time to participate.</p><p>There was a high degree of consensus about what was currently established, except when discussing immune processes. However, knowledge in this area was evolving rapidly as new evidence emerged, so as expert opinion was revised we needed to update our causal DAGs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Social roles for elicitation</head><p>There are three major specialist roles people performed during the elicitation process, which we will refer to as follows:</p><p>Modelers are our team's technical experts in BN and other computational modeling and causal inference, which encompasses model construction, refinement, comparison, learning via expert elicitation, machine learning from data, validation, and application.</p><p>Medical Experts are the domain experts we enlisted to contribute their time and knowledge, which here means medical specialists in a relevant subsystem, who agreed to participate in any of our elicitation activities.</p><p>Coordinators are people on our team with some combination of general medical knowledge, general modeling knowledge, and medical contacts, who facilitated interaction between modelers and experts, and searched the available literature to support the model-building process.</p><p>Since both medicine and modeling are highly technical, our cross-disciplinary coordinators played a vital role in translating knowledge from one sphere to the other. Also, they ensured that the modeling decisions our team made were always informed by general medical expertise even where we did not elicit specialist medical opinions on the issue. Some members of our team (YW, TS and SM) had previous experience in building causal models for infectious disease pathophysiology, including both a generalizable basic structure and adaptations for specific cases such as pneumonia. Based on a preliminary literature review, we adapted this generalizable model to form a preliminary model for COVID-19.</p><p>However, due to the recent emergence of the disease, compounded by its inherent novelty and complexity, it quickly became clear that obtaining the necessary causal knowledge would be a massive challenge. First, there was insufficient data available in the published literature to infer causal mechanisms, and the available literature was highly specialized and fragmented. Second, there was insufficient raw data available to infer causal structure more directly using machine learning techniques (such as those mentioned in Building BNs by eliciting expert opinions). Third, there was insufficient certainty amongst experts to rely on any individual source of authority; it would be more reliable to build an understanding from a group consensus, such as a group of experts in respiratory medicine. Fourth, the disease involves multiple areas of specialist knowledge, so we would need to elicit opinions from multiple groups of medical experts. Fifth, the logistical challenge of enlisting and managing multiple groups would only be compounded by needing to conduct all meetings online, due to the social effects of the very disease under discussion. Lastly, several models of specific subsystems would need to be synthesized into a single, general master model to provide the theoretical foundation for developing clinical tools. Nevertheless, we took on this difficult challenge.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Initial models</head><p>How to divide the problem into manageable models and associated groups of experts was not obvious, since medical expertise is differentiated by more than one dimension. Some medical specialists focus on particular body systems, and here early clinical experience indicated that COVID-19 strongly affected the respiratory and immune systems, with frequent complications, often involving the hematological, cardiovascular and renal systems. Clinicians, however, are familiar with the processes of diagnosis and prognosis, which need to synthesize the most important information from all these physiological systems.</p><p>Informed by our previous modeling experience and preliminary literature review, we initially divided the problem into four submodels: Core Mechanism, Complications, Immune Response, and Diagnosis. (This division was eventually revised substantially, as described in Models produced.) Our Core Mechanism submodel was focused on the respiratory system, so we primarily enlisted respiratory and infectious disease specialists to help create it. Immune Response details were elicited from clinical immunologists and other domain experts in human immunology. In contrast, to discuss Complications, we enlisted a more varied group of clinicians and other domain experts, including cardiologists, intensivists, and renal specialists. Our experts for Diagnosis were also more varied, including emergency and primary care physicians, and medical microbiologists.</p><p>To help orient our medical specialists, we provided a simple schematic Overview model indicating how these four submodels were related. However, in addition to developing the four submodels, we needed to actually synthesize them into a unified model with a view to developing practical tools to facilitate clinical reasoning and decision-making. This task was performed by our modelers in parallel, i.e., as the submodels were refined, so was the unified model.</p><p>We were able to leverage the insights from submodel workshops to connect the submodels appropriately, and to prioritize the most important features and omit less important ones. We did not use separate elicitation sessions for developing the unified model, because it was constrained to be consistent with the four submodels, it was too complex to address in a single workshop, and it also involved decisions based on modeling expertise.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Elicitation sequences</head><p>Figure <ref type="figure" target="#fig_1">3</ref> illustrates our use of several types of elicitation session in a specific sequence, and how these sessions mapped to the sequence of steps needed to develop a model.</p><p>Our first elicitation session to develop a particular expert causal model was a 2 hour group workshop, with 7-12 experts each attending for 1-2 hours. The main goal here was to develop a causal structure and refine it through interactive discussion.</p><p>Despite the fact that we did not formally elicit parameters at this stage, after the workshops it was already possible from the discussion, the literature, and our understanding to roughly indicate the expected relationships (e.g., respiratory infection is highly likely to activate the immune system) with 'indicative' BN parameters. These were useful for follow up discussion, and ensured that we specified the states of the variables properly and consolidated our understanding. We also identified some typical clinical scenarios (e.g., common ways the disease progresses).</p><p>We followed up with one-on-one sessions as needed, either with the same experts or supplementary experts with additional expertise. The goals were to clarify and refine the causal structure by discussing it directly, but also to perform a particular kind of validation exercise: checking that the proposed structure with indicative parameters accounted for the typical scenarios.</p><p>We then presented the model to independent experts in one-on-one sessions. The stated goals were the same as the previous sessions, but if the new experts' answers did not substantially differ from those of the previous experts, then this also provided a more thorough form of validation.</p><p>Finally, we sent the refined models to all the participating experts for inspection before publication. The goals were to verify widespread endorsement as a broader form of validation, and also to show participants that their efforts had yielded (if endorsed) a finished product.</p><p>Overall, 35 different experts contributed a total of 126 hours of face-to-face time to the group workshops and one-on-one meetings, with some additional activities also assisting in model development. A more detailed quantitative breakdown is as follows:</p><p>â€¢ 2 subject-matter surveys were sent out prior to early group workshops, which were answered by approximately 55 different experts.  Figure <ref type="figure">4</ref> illustrates the same sequence of elicitation session types (left column), and how they relate to two more detailed elicitation procedures. To maximize the value of each session, a sequence of associated tasks was performed before and after the session itself (middle column). This work was most extensive for the group elicitation session, and is detailed below, but the work was repeated to a lesser extent for each of the one-on-one sessions.</p><p>To conduct a group session, we followed a particular elicitation procedure (right column) guiding the introduction, efficient elicitation questions for causal structure, and the kinds of interjections from experts we encouraged. In contrast, for each one-on-one session, a customized agenda was followed with the issues and scenarios to address via more flexible interactions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Procedure around group workshop</head><p>1. Literature review: Coordinators searched for and reviewed relevant articles in the literature. They identified areas of expertise required and some controversial issues. This work continued in parallel to the next two steps.</p><p>2. Expert survey and recruitment: TS leveraged existing clinical and research networks to enlist contributions from domain experts. We directly emailed individuals as well as a national infectious diseases clinical mailing list, inviting them to complete a web-based survey (via the Survey Monkey tool). This served multiple purposes. First, it elicited initial information on the potential causal model. Since we expected many people would not fully complete the survey, we shuffled blocks of questions randomly so that we obtained a similar number of responses to all questions. Second, at the end of the Fig. <ref type="bibr" target="#b3">4</ref> Nested BN elicitation procedures. Overall, we proceeded from group workshops to final endorsement (left column). For each type of session, several tasks were performed before and after it (middle column), with more work usually required for the earlier types of session. Within the group workshops, an efficient cooperative protocol was used consistently, encompassing introductions, stimulus questions, and ad hoc responses (right column) survey, we asked if respondents wished to participate further in group workshops, so it functioned as a preparatory exercise for any participants of the workshop. Third, since it was a long survey (100 questions over 5 pages), the amount participants managed to complete was taken to be an implicit measure of their engagement. We then used other techniques to increase engagement before the workshop, such as distributing recent model diagrams and descriptions (or important excerpts), and asking a few more open-ended questions.</p><p>3. Workshop scheduling: Each week, we collectively decided which workshop to schedule next by reviewing our progress and identifying the most pressing need. We invited suitable experts with limited notice (2 weeks) but achieved good participation rates, which we attribute to a strong motivation to contribute to the pandemic response as well as, in some cases, existing relationships with our team. Since not everyone who was willing to contribute could be available at any given time, we invited more people than we could optimally accommodate, and anyone who could not attend was invited to validate the model in a subsequent round. We scheduled 2 hour timeslots, since in our experience this is the minimum to introduce experts to the technology and to the problem and still have adequate time to elicit their opinions. This is also the maximum time that most of our experts could contribute (due to limited time or attention), and most indicated a preference for shorter sessions. We tried to run the sessions as efficiently as possible, but used the full 2 hours in every case.</p><p>4. Pre-workshop preparation: Prior to each workshop, we gave participants background material that identified issues and summarized features of the model to be discussed and developed during the workshop. We used the literature review to prepare a starting template for the model. This gave our experts something to critique and expand upon, rather than starting from a blank slate, and hence expedited discussion and elicitation. We also presented a schematic overview of how each submodel would fit in with the others, and an explanation of the goals of our project.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Elicitation workshop:</head><p>We began each workshop with a short presentation that included "housekeeping" such as introductions and the format of the session, a summary of the problem space and the goals of the workshop, the starting template for the model, and any other supporting materials. We raised the general issue of what question the model is trying to answer, and tried to achieve an expert consensus on this. We then proceeded to a standard set of questions for eliciting causal structure, applied in an adaptive and iterative fashion. We asked about which factors (variables) are relevant, and only asked about their possible states if it was important to help define them. Experts frequently suggested clarification of the concepts intended to be captured by existing variables or modification of their names as elicitation progressed, and sometimes suggested merging and separating variables. We asked about the causal relationships between them, usually focusing on one variable at a time and asking which other variables are direct causes and which are direct effects (a localized version of the "bow tie" method used for risk analysis <ref type="bibr" target="#b49">[51]</ref>). When new variables were added and connected, we also asked if this superseded any prior direct connection between a parent and a child of the new variable. Experts sometimes pointed out that a relationship could be bidirectional, which we noted, but in this initial non-dynamic graph we displayed only one direction. We chose a direction that created no cycle, and was either the initial influence, or the more immediate (i.e., with less time delay), or the strongest, as deemed most informative for disease progression or most pertinent to a submodel's goal. We also noted any other comments, such as which connections were more important, unusual, or controversial. Experts sometimes clarified the basis for their suggestions by referring to the literature or their own opinion. The primary outcome of the workshop was a causal DAG (in the GeNIe BN software) that a high proportion of experts agreed captured the most important underlying pathophysiological processes.</p><p>6. Post-workshop review: After the workshop, our team had a debrief discussion (30-60 min), for feedback on their own performance and to consolidate their understanding. Subsequently, the modelers cleaned up any loose ends in the model or documentation, making sure all the knowledge elicited was understood and documented correctly, and simultaneously looking for gaps that would need further clarification. This included indicative parameters and typical scenarios, as described above. The whole workshop, conducted remotely by webbased videoconference (Zoom), was recorded as video, and the audio later transcribed into text. This allowed us to review any part of the elicitation as required. Our transcripts and video recordings, the "raw data" of these elicitation sessions, have been retained and securely stored. We used our newfound understanding to choose and schedule subsequent elicitations and actions. These included emailing questions to specific experts that were present or to other experts with different skill sets or knowledge, and then if needed, scheduling one-on-one elicitation sessions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">Translation to application models:</head><p>As a result of our various expert elicitation sessions, we produced multiple "expert models" that represented different body subsystems, and sometimes represented alternative perspectives put forward by different experts. Our approach here was exploratory, avoiding premature judgments on what would be important for practical applications, so we tried to capture this theoretical expert knowledge comprehensively. However, our ultimate aim is to develop practical tools powered by customized "application models", the first of which will be to support clinical reasoning in the prognostication for COVID-19. The expert models will provide a theoretical rationale for, and increase confidence in, the validity of the application models. Our modelers decide which aspects of the expert models are most relevant and should be included in an application model, given its purpose and required outcomes. In some respects an application model may be simplified, e.g., by combining several latent variables. In other respects, it may be more sophisticated, e.g., by creating a DBN representing the whole system based on multiple expert BNs representing subsystems. The application models we have already developed are currently being independently validated by experts, both structurally and quantitatively, as well as validated by their fit to the data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adaptive, spiral processes</head><p>Although we depict our methods as several linear sequences, our description should make clear that in combination these formed a spiral process, as widely recommended for model building: i.e., our sequences of steps were iterated to produce successive improvement. Most obviously, the sequence depicted in Fig. <ref type="figure" target="#fig_1">3</ref> is designed to successively refine and validate elements of the model through repeated elicitation.</p><p>In the same vein, we also used an adaptive elicitation procedure, i.e., we used the outcomes of elicitation and modeling exercises to help decide what sort of elicitation and modeling should be done next. So, to some extent, we learned and refined our methods over the course of the project.</p><p>One example of adaptive elicitation was modifying our pre-workshop material for participants. For our early workshops, we prepared surveys on issues where we identified disagreement in the literature. We aimed to engage and prepare participants, and obtain a preliminary understanding of their views. However, despite the assistance of our coordinators, we found it difficult to design survey questions that our modelers felt were relevant to the modeling choices, yet were framed and expressed in a way that most medical experts felt they could respond to. For example, experts often felt the answers were dependent on unstated contextual details.</p><p>For subsequent workshops, we simply gave participants background material that identified such issues of disagreement, and summarized features of the model to be discussed and developed during the workshop.</p><p>In our video conferences, where elicitation and model building were more coordinated and interactive, we found that modelers and medical experts had much less difficulty in translating medical knowledge to models and vice versa.</p><p>Another example of adaptive elicitation was adding post-workshop supplementary meetings. After holding 2 hour elicitation workshops with groups of medical experts to generate a consensus BN, it became clear that follow-up one-on-one meetings would be useful, with some of the workshop participants and sometimes with other experts who had different expertise. These meetings allowed experts who wanted additional time to give more detailed feedback on the model, and they were also a better forum for resolving persistent points of disagreement or uncertainty.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Models produced</head><p>Figure <ref type="figure" target="#fig_2">5</ref> illustrates the history of our model development in a cladogram. The four models we commenced with, as described in Methods, did not survive in their initial forms. As an adaptive, generative process in a complex, novel domain, our progress was inevitably evolutionary: new model variants were created, crossbred and adapted for each environmental niche, with many now extinct and a few still extant.</p><p>Our Core Mechanism model centered mainly on the respiratory system from the outset; as the multi-system nature of COVID-19 became apparent we decided to rename it the Respiratory model and focus on the initial infection process in that system. It is presented below.</p><p>Our Complications model largely begins where the Respiratory model's story of pathophysiology ends, capturing for more severe cases the knock-on effects to other organ systems and body functions. After a period of work on both this and the Respiratory model, key ideas were identified from both that would form the basis of an application model, called the Progression model.</p><p>This Progression model subsequently came to incorporate ideas from further expert models, including the Immune System, Vascular System and Background models, and it became clear that this BN would need to be transformed into a DBN, which can better represent longer-term system dynamics by replicating variables at different time steps (see Causal Bayesian networks), in order to track the longer-term progression of COVID-19 and ultimately assist with prognosis. The parameterized Progression model changes shape depending on the data set and setting, so it is not presented here; we are currently preparing the detailed presentation it requires. However, the expert Complications model on which it is most closely based is presented below.</p><p>We invested considerable effort in modeling the Immune System response, which proved to be a complex and contentious topic with much uncertainty and little that could be confidently extrapolated from other infections. However, after this investigation we concluded that much of the exact detail of the mediators of the immune response might be unnecessary for the purposes of diagnosis and prognosis where we ultimately aimed to contribute practical tools. Hence, we deferred work on this model and it is not presented here.</p><p>After some work eliciting details for our Diagnosis model, we made the judgment that, with the emergence of sensitive and specific diagnostics, diagnosis of patients was not a task for which our models were likely to provide much assistance, with the exception of the specific task of managing COVID-19 testing in the community. We therefore discontinued modeling most of these details, and continued modeling the remainder in our Testing model. We have already published this as a causal BN <ref type="bibr" target="#b50">[52]</ref>, and will not reproduce it here.</p><p>We detail these procedural missteps and 'dead-ends' to accurately describe a method of modeling, whereas omitting or rewriting this history might give the misleading impression that the two models presented below were always exactly the intended output.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Method of presentation</head><p>Since COVID-19 pathophysiology is complex, we developed several models for different subsystems; here we present our two main products. Our Respiratory BN concerns the detailed pathways that link the initiating infection to respiratory pathophysiology and the beginning of complications, and hence it focuses primarily on the lungs. Our Complications BN concerns higher-level interactions and how the disease may progress after complications have begun, and hence it includes other organs that become important later in the progression of a severe case.</p><p>We present the models in three complementary types of file:</p><p>1. Causal DAGs and BNs in which we specify the causal structures in static graph diagrams (Additional files 1 &amp; 2) and in GeNIe BN files (source models files can be accessed via our Open Science Framework page (OSF) project page <ref type="bibr" target="#b13">[14]</ref>). GeNIe can present the structures simply as causal DAGs, or more dynamically: variables can be displayed with their states and indicative probabilities, and the states of variables can be specified to explore how this changes the probability distributions over other variables' states.</p><p>2. BN descriptions and issues which summarize the processes these graphs represent (see Respiratory BN description and Complications BN description), and discuss a few unusual or controversial features (see Respiratory BN issues and Complications BN issues). research that supported specific BN features. We present illustrative examples in Fig. <ref type="figure" target="#fig_0">2</ref>, discuss some general features in BN Dictionaries with references, and provide the complete documents (Additional files 3 &amp; 4).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">BN dictionaries with references which give the definitions of variables and states, and also cite some of the</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations of our models</head><p>While there are still unknowns and competing hypotheses in the literature, the differences are not profound enough to require presentation as competing DAGs; our list of issues is sufficient to indicate which structural components would differ. Some disagreements only concern the degree of impact of alternative pathways, which corresponds to differing numerical parameterizations of the BNs, and no parameterizations are included here.</p><p>Both our causal DAGs do not include important background factors such as age, comorbidities and vaccination status, that strongly influence the probability of more serious COVID-19 outcomes (and each other). Knowledge about their role in the COVID-19 process was too limited: although they are known to directly influence some of our variables (e.g., vaccination reduces the chance of initial infection), not all of their direct influences are clear (e.g., vaccination also decreases the chance of infection developing into severe COVID-19, probably by influencing multiple variables along these pathways). Fortunately, these theoretical models are useful and valid without them. According to our experts' assessment, the distinctive COVID-19 causal structure depicted is unlikely to change for any particular specification of background factors. Rather, such factors will affect the parameters, e.g., how strongly some variables influence others. When adequate data is available to adjust these parameters depending on background factors, then these factors can be appended by researchers to the DAGs we present here as additional causes <ref type="foot" target="#foot_2">4</ref> .</p><p>Many variables involved in these processes are latent, but their probability distributions can be inferred from observed evidence, such as clinical signs, symptoms and laboratory measurements. Again, our BNs do not include all the relevant possible evidence available now or in the future, but our model is valid without them. Structurally, they can be appended as additional effects of some of the variables in our DAGs, without changing the existing DAG connections. As data becomes available (e.g., the false positive and false negative rates for a new test) then their CPT parameters can be estimated.</p><p>Feedback loops, i.e., variables that influence each other over time, are not included in these acyclic models. Some are, however, noted in the BN dictionary. Feedback loops, like background variables, are explicitly included in our parameterized Progression DBN for modeling longer-term COVID-19 trajectories. The details will be presented in a future publication on this model and associated practical tools.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respiratory BN description</head><p>Our Respiratory causal DAG (Additional file 1) models the physiological process underlying COVID-19 in the respiratory system, outlining multiple and often concurrent pathways from the initial replication of the virus to key downstream complications such as multi-organ failure.</p><p>We color-coded the nodes: pink for the Infection process, yellow for more detailed mechanisms relevant to the Pulmonary system, orange for those Complications that mainly arise directly from the respiratory system, and cyan for a selection of Signs and Symptoms included only for illustrative purposes. "Virus" refers to SARS-CoV-2.</p><p>References have been omitted from the following description, but can be found in the associated variable entries in the BN dictionary.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Infection process</head><p>After an exposure event, the virus can enter the upper respiratory tract via the nasopharynx (Virus enters upper respiratory tract) and may replicate locally and cause inflammation at various locations in the respiratory system, including the epithelial cells of the upper respiratory tract (Upper respiratory tract epithelial infection) and the lower respiratory tract (Alveolar epithelial infection). Direct infection involving the alveoli without preceding or simultaneous infection involving the upper respiratory tract is possible, although it may be less likely.</p><p>The virus can first become established at one site then spread to or re-establish in another. For example, Infection of olfactory epithelium following epithelial infection in the upper respiratory tract has manifested as Ageusia and/or anosmia in some patients. The virus may spread from epithelial to endothelial cells in alveoli, causing Alveolar endothelial infection. During all infection processes, the virus may enter the bloodstream (Viremia) and potentially spread to other parts of the body (not included here).</p><p>Viral replication at any site may activate Systemic immune and inflammatory response, which often results in the release of pro-and/or anti-inflammatory blood markers from immune-related cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary system</head><p>The primary function of the respiratory system is to support the metabolic processes of the body by taking in oxygen and removing carbon dioxide; this occurs through gas exchange between air and blood at the delicate membranes of the lung alveoli. Our Respiratory causal DAG (Additional file 1) models the initial pathophysiological process which is initiated by SARS-CoV-2 infection in this system.</p><p>The most notable large-scale feature is the three distinct pathways from the initial infection to involvement of the respiratory system and then complications, although these pathways have interconnections and often contribute concurrently.</p><p>Mechanical pathway: Alveolar and systemic inflammation can damage pulmonary capillaries causing the leakage of plasma (Pulmonary capillary leakage), leading to filling of the alveoli with exudate (Alveolar consolidation) that causes stiffening and reduced mechanical lung function (Reduced lung compliance), and results in Ventilatory insufficiency. Alveolar epithelial infection (and inflammation) can also directly reduce compliance, but to a lesser extent. Another possible cause of ventilatory insufficiency is a loss of muscle mass (Muscle wasting) which can be directly caused by catabolism as a result of the systemic immune response and may be affected by a range of background factors, such as nutritional status and immobility, not shown in this model.</p><p>Gas exchange pathway: Pulmonary capillary leakage and alveolar consolidation blocks the passage of air and reduces the alveolar surface area available for gas exchange, and this mismatch between ventilation and blood perfusion reduces gas exchange in the affected parts of the lungs (V/Q mismatch). At an extreme, local perfusion may occur in the absence of ventilation with oxygenated air (Shunt). Alveolar infection causes local Hypoxia which can trigger counteracting Pulmonary vasoconstriction, an adaptive physiological response which helps to match regional perfusion to ventilation in the lungs and thus reduces the extent of V/Q mismatch.</p><p>Coagulation pathway: Endothelial infection/inflammation and possibly the presence of virus in the blood (viremia) may trigger a systemic immune and inflammatory response, and this may result in an abnormally high propensity to coagulation (Hypercoagulable state). This may begin locally in the small vessels of the lower airways (Pulmonary microthromboses), but can later manifest as macroscopic thromboses in larger vessels (Other thromboses). Both types of thrombosis can block vessels in the lungs (Pulmonary circulatory blockage) and lead to V/Q mismatch, to which alveolar endothelial infection/inflammation can also directly contribute.</p><p>The direct consequences of impaired lung function, due to any of these pathways, include insufficient blood oxygenation (Hypoxemia) and excessive blood carbon dioxide (Hypercapnia), which can be measured using blood gas assays or by pulse oximetry for oxygen. Furthermore, pulmonary vasoconstriction caused by hypoxia and pulmonary circulatory obstruction caused by thrombosis can produce raised blood pressure in the pulmonary arteries (Pulmonary hypertension), which interacts with the rest of the system in a complicated way that is not explicitly described here, but which can lead to Impaired cardiac output.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Complications</head><p>The Respiratory model includes and summarizes some key complications. The lungs interact most closely with the heart; so in addition to pulmonary hypertension, pulmonary thrombosis can directly cause impaired cardiac output. Systemic immune response and insufficient oxygen in the blood (i.e., hypoxemia) can also lead to impaired cardiac output via Diminished myocardial contractility.</p><p>Maintaining end organ tissue oxygenation relies on sufficient oxygen transport via the blood, so Hypoxia occurs where there is hypoxemia or insufficient blood perfusion due to impaired cardiac output. Hypoxia can directly cause organ failure, or Multi-organ failure if more than one is affected (which is often the case).</p><p>Other pathways that can eventually lead to multi-organ failure include virus in the bloodstream causing direct viral injury to organs, and an extreme systemic immune response (i.e., cytokine storm).</p><p>Several mechanisms can trigger the body's sensor for insufficient oxygen, including reduced compliance (i.e., a mechanical failure of the lungs), hypoxemia, hypercapnia, and acidosis (both respiratory and metabolic). If the body senses there is insufficient oxygen supply (Perceived need for air), it demands more oxygen intake, which manifests as Dyspnea, one of the most important symptoms for COVID-19.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respiratory BN issues</head><p>We describe here four issues with our Respiratory model that seem noteworthy, either in themselves or as illustrative examples. Some issues involve modeling choices: even where the process being represented is entirely agreed upon, modeling sometimes involves choices about how represent it, and some of the options we chose here may need clarification or appear controversial. Some issues involve domain knowledge: there are some aspects of COVID-19 that are still not fully understood, about which there may be competing hypotheses. So, some of the options we chose here may need revision in future as further research resolves these controversies.</p><p>Upper respiratory tract mediation: One theoretical controversy, related to the diagnostic value of a dry cough, concerns three possible respiratory pathways by which the virus enters the body. Respiratory viruses are thought to typically infect the upper respiratory tract first (abbreviated as URT in the BN), then descend by contiguous spread to the alveoli and (rarely) via the bloodstream. COVID-19 may take this normal path, or may bypass the upper respiratory tract or the larger airways to infect the endothelium of the lower airways more directly via the ACE2 receptor, or less directly from the upper respiratory tract via the bloodstream. The data on this issue is currently limited so we have included all three pathways in the model, but our experts thought the typical path for respiratory viruses was less likely than the other two. Future findings may support this opinion and clarify their relative importance.</p><p>Vascular lung damage feedback loops: A high degree of vascular lung damage, caused by microthromboses in lung capillaries, appears to be a unique feature of COVID-19. Our Respiratory BN includes vascular involvement (in the Coagulation pathway) primarily as a mediator for the initial phase of infection in the lung, whereas our Complications BN places more emphasis on subsequent feedback loops. Since vascular involvement is complicated, we explored it by eliciting a separate vascular model from two of our experts, which is not presented here. We were satisfied that the vascular elements included in our Respiratory and Complications models were sufficient for our purposes.</p><p>V/Q mismatch and Shunt seem logically related: It is good practice to avoid including logically related terms in a causal model, i.e., where their semantics results in a logical dependence. Such a connection results in probabilistic dependence and an arc in the model, but it may behave differently to a causal connection under intervention, which can make it difficult to adapt the model for decision support. Here we included both Shunt and V/Q mismatch, even though shunt is (by definition) a type of V/Q mismatch, so the former logically entails the latter. This accurately represents the statements elicited: our experts consistently used both these terms and distinguished between them. They had good reason: different interventions (such as positive airway pressure for shunt and supplementary oxygen for V/Q mismatch) are considered appropriate in each case. So, mirroring their terminology faithfully captures expert knowledge in a way they can agree is accurate, which in this case includes the relevant causal connections to interventions or tests.</p><p>Neurological explanation for "happy hypoxics": We model the patient's perceived need for air separately from dyspnea (shortness of breath). An unusual feature of COVID has been patients who present as "happy hypoxics" (physiologically hypoxic but without symptoms) <ref type="bibr" target="#b51">[53]</ref>. One causal hypothesis is that neurological viral infection inhibits the perceived need for air. However, at the time of modeling this connection was very speculative, so we decided not to include this pathway, pending further medical research.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Complications BN description</head><p>Our Complications BN (Additional file 2) models the main physiological processes underlying the progression of COVID-19 from the initial infection in the respiratory system to complications in other organs. As before, the BN dictionary notes some key feedback loops and provides references for the mechanisms associated with each variable mentioned below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overview</head><p>The model explicitly describes the status (dysfunction) of nine key organ systems, namely, respiratory, vascular, cardiac, liver, kidney, hematologic, gastrointestinal, cortical and brainstem dysfunctions. Among these, we choose to paint a more fine-grained picture of the Vascular (nodes in blue) and Cardiac (nodes in green) systems due to their potential earlier involvement, as well as more significant System-wide impact (nodes in offwhite) on Other organs (nodes in orange).</p><p>The full picture of the pulmonary system is shown in the Respiratory model; here we retained a few key Pulmonary variables (nodes in yellow) and two major consequences of pulmonary dysfunction due to their system-wide impact: Hypoxemia and Hypercapnia. Two Background factors (nodes in purple) are added only for illustrative purposes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary system and direct viral impact</head><p>Despite its initial establishment in the pulmonary system, infection with SARS-CoV-2 can potentially drive the dysfunction of all listed organ systems directly via two main mechanisms, Direct viral injury and the Systemic immune/inflammatory response, throughout the entire process of the disease. In particular, they both can affect the vascular system by reducing Vascular integrity and Vascular tone. Vascular integrity refers to the status of endothelial structure compromising permeability, and the vascular tone refers to the degree of constriction of a blood vessel.</p><p>The systemic inflammatory response can additionally increase the probability of Hypercoagulable state (as also depicted in the Respiratory model) and Dehydration. For the cardiac system, direct viral injury and the systemic inflammatory response might both result in Acute cardiac inflammation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vascular system</head><p>The vascular function (in this model) represents the ability of blood vessels to ensure sufficient blood circulation to meet the metabolic needs and energy requirements of the organs. Reduced vascular tone, Reduced vascular integrity and Hypercoagulable state are three major mechanisms that contribute to vascular dysfunction.</p><p>The first two mechanisms can both lead to Reduced functional intravascular volume, i.e., less blood is available to supply the organs because of the loss of vascular tone or the shift of intravascular fluid to the interstitium (Fluid shift to interstitium) due to altered permeability (vascular integrity).</p><p>The hypercoagulable state may increase the vascular resistance to flow of blood through affected vessels. Abnormally low vascular resistance is also problematic because it can lead to insufficient pressures needed to ensure the distribution of blood and perfusion of the organs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cardiac system incl. vascular interaction</head><p>The cardiac and vascular systems closely interact. While vascular resistance and functional intravascular volume predominately drive the amount of blood available to supply organs, the heart creates the forward movement of blood needed to maintain supply to organs (organ perfusion). This is measured as Stroke volume (the volume of blood ejected for each stroke) and Cardiac output (the product of heart rate, not shown, and stroke volume).</p><p>Acute cardiac inflammation and Ischemic cardiac injury can both cause abrupt or gradual deterioration in the cardiac output, either by inducing Abnormal contractility of the heart (the strength with which it pumps), or the synchronicity and efficiency with which it pumps; the latter can be manifest as abnormal heart rate or arrhythmia.</p><p>Hypercoagulable state can lead to insufficient supply of blood more directly and acutely by blocking the pathway to certain parts of body; this can cause ischemic cardiac injury and pulmonary hypertension in the heart and lungs, respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other organ dysfunctions and failures</head><p>The ultimate need of organs is enough oxygen and metabolites supplied through the blood circulation to maintain their vital functions, we have therefore replaced Hypoxia from the Respiratory model with separate nodes that distinguish between the supply of blood (as organ perfusion) and the supply of oxygen and metabolites. Reduced supply of blood will lead to reduced supply of oxygen and metabolites, and the latter will also be reduced if there is a lack of oxygen in blood (hypoxemia) even if the supply of blood is normal.</p><p>Reduced supply of oxygen and metabolites can lead to dysfunction of any of the listed end-organs, which often further disrupts the balance of the whole system. For example, liver, kidney and gut play important roles in maintaining the balance of electrolytes, metabolites and acids. The dysfunction of these organs would generate feedback loops with other organs including pulmonary, cardiac, and vascular systems via electrolyte and metabolite imbalance and acidosis. In this model, we summarize all such feedback loops by presenting only their final deterioration to particular organ failures.</p><p>Since vascular failure is ill defined, we instead represent a key pathway in which a hypercoagulable state combined with possible liver, kidney and hematologic dysfunctions lead to general coagulopathy that can in turn contribute to severe vascular dysfunction that may result in the heart stopping and subsequent death. Critical failures of the brainstem, pulmonary, and cardiac systems also rapidly lead to an inability to support any of the vital organ functions and are terminal events.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Complications BN issues</head><p>As we did for the Respiratory model, here we describe two issues with our Complications model that seem noteworthy, involving modeling choices and/or domain knowledge.</p><p>Hypercoagulable state and Coagulability seem logically related The model includes the Boolean variable Hypercoagulable state, and also a more general variable Coagulability, which has states to represent both hypercoagulability and hypocoagulability. This reflects the way our experts consistently preferred to describe the system, and our primary goal in this model was to capture expert knowledge in a way they can agree is accurate. It may be efficient to focus on a particular state, such as hypercoagulability, where that has a higher frequency or specific effects that other states do not. However, a reasonable alternative would be to represent Coagulability twice, at two different time steps, with hypercoagulable as one possible state of this is what we use in our Progression DBN model.</p><p>Lung-acidosis feedback loop The Complications model involves several important feedback loops. For example, as noted in the description, if the lungs are damaged and do not adequately remove CO 2 , then the resulting acidosis may damage the lungs themselves.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BN Dictionaries with references</head><p>All variables in these two BNs have both descriptions and their relationships with their parent nodes (supported by selected references) specified in their Dictionaries (Additional files 3 &amp; 4); a few illustrative examples are given in Fig. <ref type="figure" target="#fig_0">2</ref>. Here we discuss some general features.</p><p>Definitions and databases Chronic pulmonary disease in Fig. <ref type="figure" target="#fig_0">2</ref> illustrates that many of our variable descriptions are explicitly aligned with the case database, e.g., IDDO <ref type="bibr" target="#b52">[54]</ref> or LEOSS <ref type="bibr" target="#b53">[55]</ref>, that we will use to parameterize both our expert and application BN models. If other researchers use slightly different descriptions and datasets, these are unlikely to alter the relevant causal connections, though different datasets in particular may not be sufficiently detailed to support each relation and, as is always the case, will need appropriate processing.</p><p>Observable versus latent Symptoms such as Ageusia and/or anosmia or test results such as Low oxygen saturation (SaO 2 ) are classified as directly observable (purple), and can often be represented as a node influenced by (and considered a noisy measurement of ) a few underlying variables, but does not itself influence those underlying processes. Hence, additional observations can usually be represented simply by adding another such variable without changing the underlying causal structure. For simplicity, we omit these variables here, with the exception of Low oxygen saturation (SaO 2 ) in the Respiratory model. Most other variables are classified as latent, even if, like Hypoxemia, their state can be easily and reliably determined via an observation like the SaO 2 test.</p><p>Number of variable states Many of our variables, such as Ageusia and/or anosmia, are Boolean: their only possible states are true or false. The names of these variables generally refer to the abnormal status of a mechanism, since people more readily interpret abnormal states as causes, particularly when they tend to produce an abnormal result <ref type="bibr" target="#b54">[56]</ref>, and to make the causal diagrams more easily digested in the absence of visible states. Most of our other variables, such as Acidosis, are ordered categorical: they have a finite number of discrete states in a meaningful order (usually degrees of severity). Continuous variables are often discretized during a measurement process and/or during BN construction to assist with probability estimation and computation (although BNs can include them). The states are not depicted in the causal DAG, but may be inspected in the BN GeNIe file.</p><p>Minimizing the state space Many variables were mentioned during elicitation and considered as candidates for inclusion, but ultimately excluded from the BN as unnecessary complications that would only make the BN harder to understand and parameterize. Several such examples exist: Electrolyte imbalance was soon replaced with the more specific Acidosis; Acute cardiac injury and Type I/II myocardial infarction were exchanged in preference for the more general Ischemic cardiac injury and Acute cardiac inflammation, along with other associated changes; several concepts surrounding innate versus adaptive immunity and finer distinctions between immune and inflammatory response were shelved in favor of a simple node Systemic immune/inflam. response representing the overall severity of the response. Similarly, we have included sufficient states to adequately represent the elicited causal relationships; adding further states would not change the causal structure significantly, but would add superfluous complexity. For example, in the Respiratory model, Hypercapnia and Acidosis are represented with just two states, while Hypoxemia and Low oxygen saturation are represented with three, due to the conclusions of that model being particularly sensitive to the latter nodes.</p><p>Qualitative vs. quantitative influence In principle, the relationships depicted in BNs can be highly complex, so a causal DAG alone could be hard to interpret without examining the details of the parameters. In practical applications such as this one, however, the reader usually has some basic domain knowledge which can be augmented by brief descriptions such as the ones we have given for the BN as a whole, and in the Dictionaries for each variable's parents. It then becomes fairly easy to interpret the kind of influence indicated by each of the arcs. For example, Upper respiratory tract epithelial infection is shown as a parent of Alveolar epithelial infection, which does not in itself indicate how the parent affects the child (unless additional markup is applied, such as plus and minus symbols), but the natural and correct reading here is that the former increases the probability of the latter. Our BN files do include parameters that roughly indicate a degree and direction of influence. These were often suggested by our experts during structure elicitation, and used to assist structure validation, but they were not formally elicited or estimated. Precise effects may vary with the local context of application, and precise parameters are often learned from an appropriate local dataset.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion and conclusion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Value of our method</head><p>Methodologically, we have demonstrated how to implement best practice recommendations in a systematic, expanded procedure for developing BNs via expert elicitation. This can be emulated, adapted and refined in future projects. It is particularly well suited to projects modeling emergent diseases, since (i) it uses large-scale online expert elicitation to develop causal structure, rather than only using data or literature directly, and (ii) it produces a family of well-documented theoretical models that make the expert knowledge freely available and that can be updated as the knowledge base develops, rather than only producing a few practical BN tools that can be derived from, and supported by, the hidden theoretical base.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Harnesses worldwide expertise when data and literature are lacking</head><p>We demonstrated how to overcome the scarcity of data, and the exceptional abundance and unreliability of research literature, by using groups of volunteer, independent, specialist domain experts to filter, interpret and discuss the literature findings and develop a reasonable current consensus. We also utilized intermediary experts to facilitate the exchange of knowledge from domain specialists to BN modelers and vice versa.</p><p>This approach is unusual, and the total number of expert hours required was exceptionally high. We obtained these hours by recruiting a large number of experts to contribute the time they could spare, which was facilitated by our extensive use of online meetings. In addition to being COVID-safe, they had the logistical advantages that experts could meet briefly within their busy schedules from their normal places of work and in highly dispersed locations, without the overhead of travel time or even needing to be in the same country, which effectively broadened our pool of available experts and the number of elicitation sessions which were feasible. Online tools also enabled all our elicitation exchanges to be easily recorded.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adaptive evolution of theoretical models that can be updated and used by others</head><p>We followed an unusual two-phase process of BN development and publication. We aimed to first elicit relatively detailed causal models that captured the experts' understanding of the relevant processes, including theoretically salient latent variables that might not be useful in the specific, practical BN tools we aimed to subsequently develop. Furthermore, we are publishing here the full details of, and documentation for, these causal models. The goal is to make the elicited expert knowledge freely available to others in a form that can be readily updated as medical science progresses, and used for a variety of purposes.</p><p>Since both the method and domain were large, complex and novel, it was necessary to subdivide, adapt and evolve both the elicitation procedure and the models. We developed a systematic approach of refining and checking the group output with one-on-one follow-up meetings as necessary, with both group members and new, independent recruits. By enlisting new domain experts, we progressively validated and refined the causal DAGs in the iterative, incremental style that is broadly recommended for BN building, but is more logistically challenging and has rarely been achieved when using expert elicitation.</p><p>Although we have specified our method in clear logical sequences, we stress that in model building, teams need to be flexible and in some respects progress is unpredictable. Pre-workshop questionnaires, which we abandoned, may prove more suited to other topics, especially where variables are known or easily identified beforehand; an elicitation workshop may reveal that substantial supplementary expertise or literature is required; it may become clear that models should be split or merged; and even after experts have signed off on a model it may need to be abandoned if subsequent testing with numerical datasets doesn't support it.</p><p>There is also scope to refine our methods further and test some variations in future applications. For example, group workshops followed by one-on-one follow ups worked well, bringing key information and model structures together quickly (via the workshops) and then allowing more cautious validation and refinement of those structures in detail (via the follow ups). However, we now believe that conducting some one-on-one interviews may be useful earlier in the elicitation process. They may be useful prior to questionnaires to increase the chance that questions handle problematic concepts well, or prior to group workshops to provide better structure for those sessions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Value of our models</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Representing current and future understanding</head><p>The two fully documented models presented here are the first published causal DAGs of COVID-19 pathophysiology. Confidence in their quality is underwritten by the rigorous process used to create them. They can be used as a visual aid to understanding and explaining the internal causal processes and remaining controversies of COVID-19, and are accessible to audiences without specialist medical expertise.</p><p>Medical science is constantly progressing, so the causal DAGs presented in this paper must be refined accordingly-possibly using the method we have provided here, whether by us or by others. Fortunately, most of our work will not need to be repeated, since elicited causal DAGs can be readily updated (see Causal Bayesian networks). This includes resolutions to the theoretical issues mentioned in Respiratory BN issues and Complications BN issues, as well as adding new background factors, new diagnostic tests, and new interventions.</p><p>Feedback loops are not incorporated in these DAGs, even though some are important for modeling the progression of the disease over longer time scales. We noted some of these loops in the Dictionaries, and will discuss them in future work, in conjunction with presenting our DBN model for disease progression.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Guiding design of empirical studies</head><p>Causal DAGs are now widely recommended to inform the design and analysis of health-related observational studies <ref type="bibr" target="#b55">[57]</ref>. DAGs help researchers identify relevant factors, and more specifically, factors that are potential mediators, confounders, and sources of selection bias or measurement error. So, we anticipate that the causal models presented in this paper will serve as a guide to the design of cohort and case-control studies of the effects of various demographic and clinical risk factors, or of the effects of various interventions, on one of several clinical outcomes of interest for SARS-CoV-2 infection. We also anticipate that these models will help data collection and standardization efforts, by identifying the issues most likely to affect any future and often unknown uses of the data, particularly causal analyses, and providing guidance on how best to avoid these issues at the data collection stage.</p><p>Causal DAGs have similar applications to the design of experimental studies, even where manipulation or randomization of the treatment variables reduces confounding. So, we anticipate that our models will also be useful to guide the design of clinical trials of treatments for SARS-CoV-2 infection.</p><p>Our DAGs can be used to identify important non-treatment factors that may influence and produce unwanted variation in the trial outcome, and which should therefore be considered for control by stratification or statistical adjustment (regardless of whether treatment randomization is employed) in order to increase the statistical power of the experiment. Similarly, our DAGs can be used to identify factors that might modify the effect of treatments, which should therefore be used to pre-specify patient subgroups.</p><p>By quantifying the pathways in our models that connect proximal outcomes such as hypoxia or biomarkers to key outcomes of interest such as the need for mechanical ventilation or death, it may be possible to design more statistically efficient trials that use the former as plausible surrogate endpoints for the latter. For example, we may use the degree to which a treatment reduces hypoxia and specific biomarkers in a larger group of patients as a more statistically powerful way of quantifying the expected reduction in the need for mechanical ventilation, which eventually occurs in a smaller subset of patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Developing and validating practical tools</head><p>Our models will be useful in the development and/or validation of fully parameterized practical tools for causal reasoning and decision support. In addition to using them for individual decision-making in a clinical setting, such tools can also be used as an aid to policy decisionmaking at a broader level, for example, by considering risks that apply to whole populations, or the effect of non-targeted interventions applied to readily identifiable patient subgroups.</p><p>Practical tools can be developed by any researchers directly from our causal DAGs, or from future updated versions of them. It is unlikely that a single dataset will contain all of the variables (and quality) required to parameterize our DAGs directly, and we do not expect the DAGs to be used in that way. Instead, we expect new models to be built based on the causal knowledge in our DAGs. We have subsequently conducted significant quantitative work in this way <ref type="foot" target="#foot_3">5</ref> . To provide guidance on how others may approach this task, we outline a brief example from this work, involving the development of a prognosis model (which we call the Progression application model) parameterized using the LEOSS database <ref type="bibr" target="#b53">[55]</ref> (and subsequently, the IDDO subset of the ISARIC database <ref type="bibr" target="#b52">[54]</ref>).</p><p>The purpose of the Progression application model is to identify patients at risk of severe outcomes among COVID-19 patients who were admitted to hospital (general ward or ICU). For this purpose, the Complications BN was deemed the most suitable starting point. While we did not have direct access to the LEOSS dataset, we were permitted to train the model remotely and had access to the dataset's schema and summary statistics. After consulting these, key organ systems and functions that had good quality data were retained -this included the pulmonary, cardiac, immune and vascular systems. One node was used to summarise the status (normal or abnormal) for each of the first three systems (these were the pulmonary function, cardiac function and systemic immune function nodes) while the vascular system was represented directly by nodes for coagulation and functional intravascular volume. Additional nodes from the causal DAGs that were considered key and which had good data were included directly into the new models -these hypoxemia, cardiac output, and end organ perfusion. All the nodes just described were linked together according to the causal pathways given by the Complications BN.</p><p>With this basic structure in place, the LEOSS dataset was then further examined to identify variables that would provide information about an organ system, and where these were identified, they were used as part of the definition of that organ system's summary node. For example, high respiratory rates were one of the attributes used to define the abnormal state of the pulmonary function node. Some of these variables had been identified in the DAGs already (such as hypercapnia for pulmonary function), but most were new and often specific to the dataset (for example, records of complications that could be attributed to cardiac dysfunction). Generally, late stage dysfunctions (i.e., those in the 'Dysfunctions and failures' section of the Complications BN) had data that was difficult to extract, and hence these were omitted. A small set of background variables (such as age and diabetes) were further added as causal influences of the organ system nodes. At this point, the model was ready for parameterization <ref type="foot" target="#foot_4">6</ref> .</p><p>While the details of the parameterization and performance testing process are beyond the scope of this paper, we note that the model was parameterized on the LEOSS dataset via a remote training process and, even without direct data access, was capable of producing predictive performance competitive with simpler, non-causal NaÃ¯ve Bayes and logistic regression models (while retaining the benefits of causal validity) <ref type="foot" target="#foot_5">7</ref> .</p><p>In addition to the work we have described, decision and utility nodes may be added to the theoretical or application models, to allow causal BNs to formally model and predict the consequences of therapeutic interventions, which is essential for clinical reasoning and decision making. As new data accrues on the impacts of such interventions, the application models can be re-parameterized to remain accurate.</p><p>Even if an application model is developed independently of our models, the dependencies this application model encodes between variables (including interventions) can be checked against our DAGs to identify any likely discrepancies. Our models thus provide a ready-made and well grounded source of theoretical validation for other research teams using different modeling methods.</p><p>In our ongoing work with these BN models, we are already developing a range of our own tools for either standalone or integrated decision support, including the Progression application model described above, based on both the LEOSS and IDDO databases. We are tailoring two distinct tools based on an applied version of the models we have described here, one for in-hospital prognosis and management of COVID-19 patients and another to support resource management and monitoring for confirmed cases. For the in-hospital prognosis tool, available information about the patient can be entered into the tool by a clinician directly, or retrieved automatically from a patient's record. The clinician will then receive information not just on the patient's overall prognosis, but also on risks around organs, body functions and treatment requirements over the next 24 hours and the next 5 days. For resource management, the same application model can be used, but integrated into existing, centralized, government monitoring systems. The model would be used for confirmed cases being monitored at home or in non-medical facilities to quickly flag those at risk, allowing ministry staff to make better informed and more fine-grained decisions around utilization of hospital and medical resources.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 2</head><label>2</label><figDesc>Fig. 2 BN Dictionary excerpt. In the Dictionaries, descriptions of the variables and arcs are provided, with selected supporting references. The variables are numbered, named and color coded as in the causal DAGs and BN files. The full Dictionaries are provided as Additional files 3 &amp; 4</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 3</head><label>3</label><figDesc>Fig. 3 Model development process. Typical steps in our model development, and their relationship to our elicitation sessions</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 5</head><label>5</label><figDesc>Fig. 5 Model cladogram from April to December 2020. Some model lines primarily concerned prognosis (top family), other lines primarily concerned diagnosis (middle), and one line concerns NaÃ¯ve Bayes (NB) and related variants adapted for preliminary parameterization and data exploration using available data (bottom)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc>â€¢ 7 group workshops were held in which 26 different experts participated (some attending more than one), contributing a total of 106 hours. â€¢ 15 one-on-one follow-up meetings were held (occasionally two experts attended a meeting) in which 15 different experts participated, contributing a total of 20 hours. Where one-on-one meetings focused on reviewing a model produced in a group workshop (11/15 meetings), these almost always (10/11) involved new experts who had not already participated in developing the model discussed. â€¢ After the structures of the expert BNs had been determined, there were subsequent meetings (11 meetings involving 35 different experts contributing a total of 85 hours) focused mainly on param-</figDesc><table /><note><p>eterization of our Progression model via available databases, which provided as a byproduct some additional degree of detail and validation for the experts' theoretical causal BNs presented here, e.g., for the definitions of some of the variable states.</p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1" xml:id="foot_0"><p>This work is to be published. An initial report can be found at https:// osf. io/ mdve7/.</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2" xml:id="foot_1"><p>In mathematical graph theory, where early work focused on polyhedra, these are traditionally called 'vertices' connected by 'directed edges'; but common and equivalent terms are 'nodes' connected by 'directed links' , 'arrows' or 'arcs' .</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="4" xml:id="foot_2"><p>We implemented this procedure in the subsequent development of our parameterized Progression DBN. We conducted a survey and group elicitation session dedicated to background factors, where we asked experts which of the Progression variables (which do not include all the theoretical variables here) would be affected.</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="5" xml:id="foot_3"><p>Publication of this work is upcoming. For an initial report, including development, analysis and validation, see https:// osf. io/ mdve7/.</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="6" xml:id="foot_4"><p>The final application model structure can be found at https:// osf. io/ mdve7/.</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="7" xml:id="foot_5"><p>Of greater interest would be a comparison with other causal models, but these are generally lacking in the literature. We did make comparisons with putative causal structures learned automatically (and remotely) from the LEOSS dataset (using the PC<ref type="bibr" target="#b12">[13]</ref> and CaMML<ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b65">67]</ref> algorithms). However, while these had very good predictive performance, the number of variables shared with our models was not sufficient to allow them to independently produce reliable causal structures to assess the causal relationships in our DAGs.</p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgements</head><p>We thank all experts and our <rs type="institution">COVID BN Advisory Group</rs> who participated in the elicitation sessions including surveys, group workshops, and one-on-one meetings. The members of the advisory group are listed in Additional file 5. We also thank <rs type="person">Dr Sally Shrapnel</rs> for helpful feedback on the draft of this article.</p></div>
			</div>
			<div type="funding">
<div><head>Funding</head><p>This publication is supported by <rs type="funder">Digital Health CRC</rs> Limited funded under the <rs type="funder">Australian Commonwealth Government's Cooperative Research Centres Programme</rs> and The <rs type="funder">Snow Medical Research Foundation</rs>.</p></div>
			</div>
			<listOrg type="funding">
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p>All source models and associated dictionaries are accessible as additional files to the manuscript, and via our Open Science Framework page: osf.io/bynr6 <ref type="bibr" target="#b13">[14]</ref>.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BN</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Information</head><p>The online version contains supplementary material available at <ref type="url" target="https://doi">https:// doi</ref>. org/ 10. 1186/ s12874-023-01856-1.</p><p>All the following additional files will remain available on our OSF project page <ref type="bibr" target="#b13">[14]</ref> in the versions referred to here, accompanied by any subsequent versions of them that we develop.</p><p>Additional file 1.Respiratory causal DAG v3.8. This depicts the initial pathophysiological process of SARS-CoV-2 in the respiratory system, outlining multiple and often concurrent pathways from viral infection to key downstream complications such as multi-organ failure. Some variables are latent (i.e., not directly observable) but their probability distributions can be inferred from observable evidence such as clinical signs, symptoms and laboratory measurements, not all of which are shown in the diagram. Many mechanisms described in the BN can be influenced by background factors such as age, sex, and comorbidities, which are also not shown. BNs are acyclic, so feedback loops that may occur as the disease progresses are not included in the diagram. We divide the nodes into four color-coded categories: Infection process (pink), Pulmonary details (yellow), resulting Complications (orange), and a few illustrative examples of Signs and symptoms (cyan). Within the pulmonary system, we distinguish (using background boxes) three pathways from Infection to possible Complications: involving problems with Mechanical operation of the lungs, Gas exchange, and Coagulation.</p><p>Additional file causal DAG v3.8. This depicts the main physiological processes underlying the progression of COVID-19 from the initial infection in the Pulmonary system (nodes in yellow) to complications in other organs. Vascular (nodes in blue) and Cardiac (nodes in green) systems are modeled in more detail due to their likely earlier involvement and greater system-wide impact on Other Organs (nodes in orange), i.e., liver, kidney, hematologic, gastrointestinal, cortical and brainstem dysfunction. Mechanisms that have a system-wide impact are colored in off-white, and we include two illustrative examples of background factors (nodes in purple).</p><p>Additional file 3.Respiratory BN dictionary v3.8. This table for the Respiratory BN specifies, for each variable, a description of the variable and its relationships to its parent nodes, supported by references to academic literature listed in a bibliography. Relevant evidence, background factors, and some feedback loops are noted even if not included in the BN diagram.</p><p>Additional file 4.Complications BN dictionary v3.8. This table for the Complications BN specifies, for each variable, a description of the variable and its relationships to its parent nodes, supported by references to academic literature listed in a bibliography. Relevant evidence, background factors, and some feedback loops are noted even if not included in the BN diagram.</p><p>Additional file 5. Members of COVID BN Advisory Group v1.2. This table lists all the members of our COVID BN Advisory Group who opted to be individually acknowledged, with their institutions and relevant qualifications.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p>TS and AEN initiated the project. TLS, AEN, SM and YW designed the project. SM, YW, OW led the knowledge elicitation, data interpretation, and modeling activities. TLS, AOM, DAF and the COVID BN Advisory Group participated in the modeling as domain experts, and contributed to data interpretation. JAR and RP acquired the data, and JAR contributed to data interpretation. EPN led the manuscript writing. All authors have reviewed and approved the final manuscript.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Declarations Ethics approval and consent to participate</head><p>All methods were performed in accordance with the relevant guidelines and regulations. Ethics approval was granted by the Monash University Human Research Ethics Committee (Project ID 26942). Informed consent was obtained from all participants of the study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p>The authors declare that they have no competing interests.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publisher's Note</head><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The carnage of substandard research during the COVID-19 pandemic: a call for quality</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Bramstedt</surname></persName>
		</author>
		<idno type="DOI">10.1136/medethics-2020-106494</idno>
		<ptr target="https://doi.org/10.1136/medethics-2020-106494" />
	</analytic>
	<monogr>
		<title level="j">J Med Ethics</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="803" to="807" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Bayesian Artificial Intelligence. 2nd ed</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Korb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
			<publisher>Chapman &amp; Hall / CRC Press</publisher>
			<pubPlace>Boca Raton</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Computer Science &amp; Data Analysis</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Dynamic models for Coronavirus Disease 2019 and data analysis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chen</forename><forename type="middle">W</forename></persName>
		</author>
		<idno type="DOI">10.1002/mma.6345</idno>
		<ptr target="https://doi.org/10.1002/mma.6345" />
	</analytic>
	<monogr>
		<title level="j">Math Methods Appl Sci</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="4943" to="4949" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Novel Coronavirus 2019 (Covid-19) epidemic scale estimation: topological network-based infection dynamics model. medRxiv</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1101/2020.02.20.20023572</idno>
		<ptr target="https://doi.org/10.1101/2020.02.20" />
		<imprint>
			<date type="published" when="2020">2020. 20023</date>
			<biblScope unit="page">572</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fitzpatrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chinazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Piontti</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2468-2667(21)00002-5</idno>
		<ptr target="https://doi.org/10.1016/S2468-2667" />
	</analytic>
	<monogr>
		<title level="j">Lancet Public Health</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Modelling the impact of COVID-19 on intensive care services in New South Wales</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Trauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mcbryde</surname></persName>
		</author>
		<idno type="DOI">10.5694/mja2.50606</idno>
		<ptr target="https://doi.org/10.5694/mja2.50606" />
	</analytic>
	<monogr>
		<title level="j">Med J Aust</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="468" to="469" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Early dynamics of transmission and control of COVID-19: a mathematical modelling study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kucharski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Diamond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Edmunds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Funk</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(20)30144-4</idno>
		<ptr target="https://doi.org/10.1016/S1473-3099" />
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="30144" to="30144" />
			<date type="published" when="2020">2020. 2020</date>
		</imprint>
	</monogr>
	<note>Lancet Infect Dis</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Risk estimation and prediction of the transmission of coronavirus disease-2019 (COVID-19) in the mainland of China excluding Hubei province</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s40249-020-00683-6</idno>
		<ptr target="https://doi.org/10.1186/s40249-020-00683-6" />
	</analytic>
	<monogr>
		<title level="j">Infect Dis Poverty</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">116</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">Dynamic causal modelling of COVID-19</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Friston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Parr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zeidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Razi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Flandin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Daunizeau</surname></persName>
		</author>
		<idno>arXiv. 2020: 2004-04463</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Estimating required &apos;lockdown&apos; cycles before immunity to SARS-CoV-2: Model-based analyses of susceptible population sizes</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Fagerholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Daunizeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Williams</surname></persName>
		</author>
		<idno>arXiv. 2020: 2004-05060</idno>
	</analytic>
	<monogr>
		<title level="m">seven European countries including the UK and Ireland</title>
		<imprint/>
	</monogr>
	<note>S0</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">COVID-19 infection and death rates: the need to incorporate causal explanations for the data and avoid bias in testing</title>
		<author>
			<persName><forename type="first">N</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Neil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Osman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mclachlan</surname></persName>
		</author>
		<idno type="DOI">10.1080/13669877.2020.1756381</idno>
		<ptr target="https://doi.org/10.1080/13669877" />
	</analytic>
	<monogr>
		<title level="j">J Risk Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">81</biblScope>
			<date type="published" when="2020">2020. 2020. 17563</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference</title>
		<author>
			<persName><forename type="first">J</forename><surname>Pearl</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1988">1988</date>
			<publisher>Morgan Kaufmann</publisher>
			<pubPlace>San Mateo</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<author>
			<persName><forename type="first">P</forename><surname>Spirtes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Glymour</surname></persName>
		</author>
		<title level="m">Scheines R. Causation, Prediction, and Search. 2nd ed</title>
		<meeting><address><addrLine>Cambridge</addrLine></address></meeting>
		<imprint>
			<publisher>MIT Press</publisher>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<author>
			<persName><surname>Covid-Intelligence</surname></persName>
		</author>
		<ptr target="https://osf.io" />
		<title level="m">Decision-Support Using Bayesian Networks/BN -respiratory and complications</title>
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The ethics of artificial intelligence</title>
		<author>
			<persName><forename type="first">N</forename><surname>Bostrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yudkowsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The Cambridge Handbook of Artificial Intelligence</title>
		<editor>
			<persName><forename type="first">K</forename><surname>Frankish</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Ramsey</surname></persName>
		</editor>
		<meeting><address><addrLine>Cambridge</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="2014">2014</date>
			<biblScope unit="page" from="316" to="334" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Explaining Bayesian Networks in Natural Language: State of the Art and Challenges</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hennessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>BugarÃ­n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Reiter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">2nd Workshop on Interactive Natural Language Technology for Explainable Artificial Intelligence</title>
		<meeting><address><addrLine>Dublin</addrLine></address></meeting>
		<imprint>
			<publisher>Association for Computational Linguistics</publisher>
			<date type="published" when="2020">2020</date>
			<biblScope unit="page" from="28" to="33" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A method for explaining Bayesian networks for legal evidence with scenarios</title>
		<author>
			<persName><forename type="first">C</forename><surname>Vlek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Prakken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Renooij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Verheij</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10506-016-9183-4</idno>
		<ptr target="https://doi.org/10.1007/s10506-016-9183-4" />
	</analytic>
	<monogr>
		<title level="j">Artif Intell Law</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="285" to="324" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Explainable Bayesian Network Query Results via Natural Language Generation Systems</title>
		<author>
			<persName><forename type="first">J</forename><surname>Keppens</surname></persName>
		</author>
		<idno type="DOI">10.1145/3322640.3326716</idno>
		<ptr target="https://doi.org/10.1145/33226" />
	</analytic>
	<monogr>
		<title level="m">Proceedings of the Seventeenth International Conference on Artificial Intelligence and Law. ICAIL</title>
		<meeting>the Seventeenth International Conference on Artificial Intelligence and Law. ICAIL<address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Association for Computing Machinery</publisher>
			<date type="published" when="2019">2019</date>
			<biblScope unit="volume">33267</biblScope>
			<biblScope unit="page">16</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">A Progressive Explanation of Inference in &apos;Hybrid&apos; Bayesian Networks for Supporting Clinical Decision Making</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kyrimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Marsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Probabilistic Graphical Models -Eighth International Conference (PGM 2016)</title>
		<editor>
			<persName><forename type="first">A</forename><surname>Antonucci</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Corani</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>De Campos</surname></persName>
		</editor>
		<meeting><address><addrLine>Lugano, Switzerland</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016">September 6-9, 2016. 2016</date>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="275" to="286" />
		</imprint>
	</monogr>
	<note>Proceedings. JMLR Workshop and Conference Proceedings</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">BARD: A Structured Technique for Group Elicitation of Bayesian Networks to Support Analytic Reasoning</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Nyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Korb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wybrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Zukerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mascaro</surname></persName>
		</author>
		<idno type="DOI">10.1111/risa.13759</idno>
		<ptr target="https://doi.org/10.1111/risa.13759" />
	</analytic>
	<monogr>
		<title level="m">Special Issue: Bayesian networks for risk analysis and decision-support</title>
		<imprint>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Human-Centric Justification of Machine Learning Predictions</title>
		<author>
			<persName><forename type="first">O</forename><surname>Biran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mckeown</surname></persName>
		</author>
		<idno type="DOI">10.24963/ijcai.2017/202</idno>
		<ptr target="https://doi.org/10.24963/ijcai.2017/202" />
	</analytic>
	<monogr>
		<title level="m">Proceedings of the Twenty-Sixth International Joint Conference on Artificial Intelligence</title>
		<meeting>the Twenty-Sixth International Joint Conference on Artificial Intelligence</meeting>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1461" to="1467" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Improving the accuracy of medical diagnosis with causal machine learning</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Richens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Johri</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-020-17419-7</idno>
		<ptr target="https://doi.org/10.1038/s41467-020-17419-7" />
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">3923</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Learning Hybrid Bayesian Networks by MML</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Allison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Korb</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">AI 2006: Advances in Artificial Intelligence</title>
		<editor>
			<persName><forename type="first">A</forename><surname>Sattar</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">B</forename><surname>Kang</surname></persName>
		</editor>
		<meeting><address><addrLine>Berlin</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2006">2006</date>
			<biblScope unit="page" from="192" to="203" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Bayesian belief nets for managing expert judgement and modelling reliability</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Sigurdsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Walls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Quigley</surname></persName>
		</author>
		<idno type="DOI">10.1002/qre.410</idno>
		<ptr target="https://doi.org/10.1002/qre.410" />
	</analytic>
	<monogr>
		<title level="j">Qual Reliab Eng Int</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="181" to="190" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Bayesian networks in reliability</title>
		<author>
			<persName><forename type="first">H</forename><surname>Langseth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Portinale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Reliab Eng Syst Saf</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="92" to="108" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Modelling spatial and temporal changes with GIS and Spatial and Dynamic Bayesian Networks</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">E</forename><surname>Chee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Quintana-Ascencio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Fauth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hall</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.envsoft.2016.04.012</idno>
		<ptr target="https://doi.org/10.1016/j.envsoft.2016.04.012" />
	</analytic>
	<monogr>
		<title level="m">Environ Model Softw</title>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="108" to="120" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Individual versus group decision making: Jurors&apos; reliance on central and peripheral information to evaluate expert testimony</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Salerno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Bottoms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Peter-Hagene</forename><surname>Lc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">183580</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Are groups more rational than individuals? A review of interactive decision making in groups</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kugler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Kausel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kocher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Wiley Interdiscip Rev Cogn Sci</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="471" to="482" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Groups make better self-interested decisions</title>
		<author>
			<persName><forename type="first">G</forename><surname>Charness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sutter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Econ Perspect</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="157" to="176" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The group matters: A review of processes and outcomes in intelligence analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Straus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bruce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Group Dyn: Theory Res Pract</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">128</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><surname>32</surname></persName>
		</author>
		<title level="m">Group behavior and performance</title>
		<editor>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Fiske</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Gilbert</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Lindzey</surname></persName>
		</editor>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Wiley</publisher>
			<date type="published" when="2010">2010</date>
			<biblScope unit="page" from="1208" to="1251" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The Robust Beauty of Majority Rules in Group Decisions</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hastie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kameda</surname></persName>
		</author>
		<idno type="DOI">10.1037/0033-295X.112.2.494</idno>
		<ptr target="https://doi.org/10.1037/0033-295X.112.2.494" />
	</analytic>
	<monogr>
		<title level="j">Psychol Rev</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="494" to="508" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<author>
			<persName><forename type="first">D</forename><surname>Kahneman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Slovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tversky</surname></persName>
		</author>
		<title level="m">Judgment Under Uncertainty: Heuristics and Biases</title>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Counteracting anchoring effects in group decision making</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stettinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Felfernig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Leitner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Reiterer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">23rd International Conference on User Modeling, Adaptation, and Personalization</title>
		<meeting><address><addrLine>Cham</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2015">2015. 2015</date>
			<biblScope unit="page" from="118" to="130" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Errors in creative thought? Cognitive biases in a complex processing activity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Mumford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Blair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Leritz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Osburn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Creat Behav</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="75" to="109" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Avoiding groupthink: Whereas weakly identified members remain silent, strongly identified members dissent about collective problems</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Packer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychol Sci</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="546" to="548" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Is Out of Sight, Out of Mind? An Empirical Study of Social Loafing in Technology-Supported Groups</title>
		<author>
			<persName><forename type="first">L</forename><surname>Chidambaram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Tung</surname></persName>
		</author>
		<idno type="DOI">10.1287/isre.1050.0051</idno>
		<ptr target="https://doi.org/10.1287/isre.1050.0051" />
	</analytic>
	<monogr>
		<title level="j">Inf Syst Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="149" to="168" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">The Delphi Method: Techniques and Applications</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Linstone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Turoff</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1975">1975</date>
			<publisher>Addison-Wesley</publisher>
			<pubPlace>London</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Delphi: a reevaluation of research and theory</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bolger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Technol Forecast Soc Chang</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="235" to="251" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Network fragments: Representing knowledge for constructing probabilistic models</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Laskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Mahoney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the Thirteenth Conference on Uncertainty in Artificial Intelligence, UAI&apos;97</title>
		<meeting>the Thirteenth Conference on Uncertainty in Artificial Intelligence, UAI&apos;97<address><addrLine>San Francisco</addrLine></address></meeting>
		<imprint>
			<publisher>Morgan Kaufmann</publisher>
			<date type="published" when="1997">1997</date>
			<biblScope unit="page" from="334" to="341" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Network engineering for agile belief network models</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Laskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Mahoney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">IEEE Trans Knowl Data Eng</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="487" to="498" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title level="m" type="main">Ontology and Bayesian decision networks for supporting the meteorological forecasting process</title>
		<author>
			<persName><forename type="first">T</forename><surname>Boneh</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
			<pubPlace>Melbourne</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Monash University</orgName>
		</respStmt>
	</monogr>
	<note type="report_type">Phd thesis</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Jury Fallacy&quot; and the use of Bayesian Networks to present Probabilistic Legal Arguments</title>
		<author>
			<persName><forename type="first">N</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Neil</forename><forename type="middle">M</forename><surname>The</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Math Today</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="61" to="102" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">A spiral model of software development and enhancement</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Boehm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Computer</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="61" to="72" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">Object-Oriented Programming; An Evolutionary Approach. 2nd ed. USA</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Novobilski</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1991">1991</date>
			<publisher>Addison-Wesley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Application of a technique for research and development program evaluation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Malcolm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Roseboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Fazar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oper Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="646" to="649" />
			<date type="published" when="1959">1959</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Overconfidence in interval estimates</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Soll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Klayman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Psychol Learn Mem Cogn</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="299" to="314" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Reducing overconfidence in the interval judgments of experts</title>
		<author>
			<persName><forename type="first">A</forename><surname>Speirs-Bridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fidler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Flander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cumming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Burgman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Risk Anal</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="512" to="523" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A practical guide to structured expert elicitation using the IDEA protocol</title>
		<author>
			<persName><forename type="first">V</forename><surname>Hemming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Burgman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Hanea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Wintle</surname></persName>
		</author>
		<idno type="DOI">10.1111/2041-210X.12857</idno>
		<ptr target="https://doi.org/10.1111/2041-210X.12857" />
	</analytic>
	<monogr>
		<title level="j">Methods Ecol Evol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="169" to="180" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">The bowtie method: A review</title>
		<author>
			<persName><forename type="first">A</forename><surname>De Ruijter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guldenmund</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ssci.2016.03.001</idno>
		<ptr target="https://doi.org/10.1016/j.ssci.2016.03.001" />
	</analytic>
	<monogr>
		<title level="j">Saf Sci</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="211" to="218" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Bridging the gaps in test interpretation of SARS-CoV-2 through Bayesian network modelling</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Foley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ramsay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Woodberry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mascaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
		</author>
		<idno type="DOI">10.1017/S0950268821001357</idno>
		<ptr target="https://doi.org/10.1017/S0950" />
	</analytic>
	<monogr>
		<title level="j">Epidemiol Infect</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="26882" to="10013" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">The pathophysiology of &apos;happy&apos; hypoxemia in COVID-19</title>
		<author>
			<persName><forename type="first">S</forename><surname>Dhont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Derom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Braeckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Depuydt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lambrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respir Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">Infectious Diseases Data Observatory (IDDO)</title>
		<ptr target="https://www.iddo.org/covid-19" />
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<monogr>
		<ptr target="https://leoss.net/" />
		<title level="m">Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS)</title>
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Cause and Norm</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hitchcock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Knobe</surname></persName>
		</author>
		<idno type="DOI">10.5840/jphil20091061128</idno>
		<ptr target="https://doi.org/10.5840/jphil" />
	</analytic>
	<monogr>
		<title level="j">J Philos</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="587" to="612" />
			<date type="published" when="2009">2009. 20091 061128</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations</title>
		<author>
			<persName><forename type="first">Pwg</forename><surname>Tennant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Berrie</forename><forename type="middle">L</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Gadd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename></persName>
		</author>
		<idno type="DOI">10.1093/ije/dyaa213</idno>
		<ptr target="https://doi.org/10.1093/ije/dyaa213" />
	</analytic>
	<monogr>
		<title level="j">Int J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="620" to="632" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title/>
		<author>
			<orgName type="collaboration">GeNIe</orgName>
		</author>
		<ptr target="https://www.bayesfusion.com/" />
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<ptr target="https://www.norsys.com/" />
		<title level="m">Netica software</title>
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hugin Software</surname></persName>
		</author>
		<ptr target="https://www.hugin.com/" />
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title/>
		<author>
			<persName><surname>Agenarisk Software</surname></persName>
		</author>
		<ptr target="https://www.agenarisk.com/" />
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<monogr>
		<ptr target="http://www.bayesia.com/" />
		<title level="m">Bayesia software</title>
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<monogr>
		<ptr target="http://leo.ugr.es/elvira/" />
		<title level="m">Elvira software</title>
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<monogr>
		<ptr target="https://github.com/bayesnet/bnt" />
		<title level="m">Bayes Net Toolbox for Matlab</title>
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<monogr>
		<ptr target="http://reasoning.cs.ucla.edu/samiam/" />
		<title level="m">SamIam software</title>
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<ptr target="https://pypi.org/project/bayespy/" />
		<title level="m">BayesPy: tools for Bayesian inference with Python</title>
		<imprint>
			<date type="published" when="2022-04-18">18 Apr 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Causal discovery via MML</title>
		<author>
			<persName><forename type="first">C</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Korb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">ICML</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="516" to="524" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
